Insider Buying: Cue Biopharma, Inc. (NASDAQ:CUE) CEO Acquires 30,000 Shares of Stock

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Daniel R. Passeri acquired 30,000 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was bought at an average cost of $1.03 per share, for a total transaction of $30,900.00. Following the completion of the purchase, the chief executive officer now directly owns 164,578 shares in the company, valued at $169,515.34. This represents a 22.29 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Cue Biopharma Stock Performance

NASDAQ CUE traded up $0.01 during trading on Wednesday, hitting $1.07. The company’s stock had a trading volume of 414,263 shares, compared to its average volume of 453,138. Cue Biopharma, Inc. has a 52 week low of $0.45 and a 52 week high of $3.20. The firm has a market cap of $67.78 million, a P/E ratio of -1.19 and a beta of 1.66. The firm has a 50 day moving average price of $1.32 and a 200 day moving average price of $1.05. The company has a quick ratio of 2.22, a current ratio of 2.22 and a debt-to-equity ratio of 0.05.

Analysts Set New Price Targets

Separately, Stifel Nicolaus dropped their price target on shares of Cue Biopharma from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $5.00.

Hedge Funds Weigh In On Cue Biopharma

Several large investors have recently bought and sold shares of the stock. GSA Capital Partners LLP raised its holdings in Cue Biopharma by 5.1% in the 3rd quarter. GSA Capital Partners LLP now owns 291,663 shares of the company’s stock valued at $221,000 after acquiring an additional 14,104 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Cue Biopharma by 3.3% during the third quarter. Geode Capital Management LLC now owns 508,827 shares of the company’s stock valued at $385,000 after purchasing an additional 16,371 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Cue Biopharma in the second quarter valued at $66,000. Good Life Advisors LLC lifted its position in Cue Biopharma by 23.1% in the third quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock worth $303,000 after purchasing an additional 75,000 shares during the period. Finally, Sigma Planning Corp boosted its stake in Cue Biopharma by 50.9% during the third quarter. Sigma Planning Corp now owns 401,325 shares of the company’s stock worth $304,000 after buying an additional 135,295 shares in the last quarter. 35.04% of the stock is currently owned by institutional investors and hedge funds.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.